- Obesity drug beloranib shows promise in Prader-Willi population in Phase 2 trials
- Study: Whooping cough vaccine may not prevent infection
- Mintel: Energy drink category up despite health concerns
- MarketsandMarkets projects the nutraceutical ingredient market to reach $33.6 billion by 2018
- Reports: Bill to extend federal regulations for compounding pharmacies expected to pass House, Senate
SILVER SPRING, Md. — The Food and Drug Administration has approved a new weight-loss drug made by Vivus, the agency said.
The FDA announced the approval of Qsymia (phentermine and topiramate) extended-release, designed for use by overweight and obese adults alongside a reduced-calorie diet and exercise for chronic weight management. The drug's original brand name was Qnexa.
"Obesity threatens the overall well-being of patients and is a major public health concern," FDA Center for Drug Evaluation and Research director Janet Woodcock said. "Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition."